 |
 |
||||||||
|
|||||||||
|
|||||||||
 |
 |
||||||||
|
 |
Paratek has chosen a two-pronged strategy for commercializing our novel anti-infective and other therapeutic products. The first prong of Paratek’s strategy, aimed at the largest therapeutic markets, is to develop partnerships with established pharmaceutical and biotechnology companies that have the capability and substantial infrastructure to successfully market products to thousands of hospitals and physicians around the world. These partners would help guide clinical development efforts and interactions with regulatory agencies and would share the expenses associated with pharmaceutical development and commercialization. The second prong of Paratek’s commercialization strategy is to commercialize on our own or through co-marketing arrangements anti-infective products aimed at markets that Paratek can approach with our own sharply focused development and marketing effort. Paratek is always interested in discussing opportunities for additional strategic alliances with pharmaceutical and biotechnology companies to assist in the development and commercialization of our lead candidates. For more information, please contact bd@paratekpharm.com. |